Macquarie Group’s CytomX Therapeutics CTMX Stock Holding History

Macquarie Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,134	Closed	-$2	–	1952
2024 Q1	$2	Buy	+1,134	New	+$2.09K	﹤0.01%	1845
2021 Q4	–	Sell	-4,853	Closed	-$25K	–	2613
2021 Q3	$25K	Buy	4,853 +4,064	+515%	+$21.8K	﹤0.01%	2403
2021 Q2	$5K	Hold	789	–	–	﹤0.01%	2525
2021 Q1	$6K	Sell	789 -374	-32%	-$2.96K	﹤0.01%	2435
2020 Q4	$8K	Hold	1,163	–	–	﹤0.01%	2322
2020 Q3	$8K	Hold	1,163	–	–	﹤0.01%	2298
2020 Q2	$10K	Buy	+1,163	New	+$10.8K	﹤0.01%	2286
2018 Q3	–	Sell	-700	Closed	-$16K	–	2175
2018 Q2	$16K	Buy	+700	New	+$17.9K	﹤0.01%	2085
2018 Q1	–	Sell	-22,000	Closed	-$464K	–	2208
2017 Q4	$464K	Buy	22,000 +16,100	+273%	+$334K	﹤0.01%	1462
2017 Q3	$107K	Buy	+5,900	New	+$92.1K	﹤0.01%	1904

Other funds holding CTMX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Macquarie Group's CTMX Position: Q2 2024 in Review

Macquarie Group sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 1,134 shares — an estimated $2 sold.

Macquarie Group first reported a position in CTMX in Q3 2017 and held it in 10 quarters. The position peaked at $464K in Q4 2017. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

Macquarie Group reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,134 CytomX Therapeutics shares in Q2 2024, an estimated $2.
Macquarie Group first reported a position in CytomX Therapeutics in Q3 2017 and held it in 10 quarters.
Macquarie Group's CytomX Therapeutics position peaked at $464K in Q4 2017.
74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.